IBCL-131: inMIND: A Phase 3 Study of Tafasitamab + Lenalidomide Add-On to Rituximab vs Placebo + Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 21; p. S402
• Main Authors: Sehn, Laurie H., Scholz, Christian W., Luminari, Stefano, Salar, Antonio, Wahlin, Björn E., Gopal, Ajay K., Bonnet, Christophe, Trneny, Marek, Paneesha, Shankara, Manzke, Oliver, Seguy, Francis, Li, Di, Hübel, Kai
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2021
• Subjects: follicular lymphoma; IBCL; marginal zone lymphoma; non-Hodgkin lymphoma; tafasitamab; IBCL; non-Hodgkin lymphoma; follicular lymphoma; tafasitamab; marginal zone lymphoma
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/S2152-2650(21)01908-X

Treatment options for patients with R/R FL or MZL are limited. Tafasitamab is an Fc-engineered humanized monoclonal antibody against CD19, which is broadly expressed in FL and MZL and regulates B-cell proliferation. Tafasitamab monotherapy showed clinical activity in a phase 2a study (NCT01685008), with an ORR of 29% (n/N=10/34) and 33% (n/N=3/9) in patients with FL and MZL, respectively. In an ongoing phase 2 study (L-MIND, NCT02399085), tafasitamab plus lenalidomide (LEN) followed by tafasitamab alone demonstrated an ORR of 57.5% (n/N=46/80) in patients with R/R diffuse large B-cell lymphoma (indication received accelerated FDA approval). These observations suggest potential clinical benefit of tafasitamab plus LEN for patients with R/R FL or MZL. To investigate efficacy and safety of tafasitamab plus LEN as add-on to rituximab compared with LEN alone added to rituximab in patients with R/R FL or R/R MZL. Multicenter, global, randomized, double-blind, placebo-controlled, phase 3 study. ≥18 years with histologically confirmed FL (grade 1, 2, or 3a) or MZL (nodal, splenic, or extranodal), documented R/R disease, ≥1 prior systemic anti-CD20 therapy (including anti-CD20 refractory disease), ECOG PS ≤2, in need of treatment per GELF criteria. Exclusions include prior rituximab plus LEN combination treatment, history of nonhematologic malignancy, congestive heart failure, or known CNS lymphoma. inMIND (NCT04680052, EudraCT2020-004407-13) is currently enrolling, with planned enrollment of 528 R/R FL and 60–90 R/R MZL patients. Patients will be randomized 1:1 to receive tafasitamab (12 mg/kg IV on days 1, 8, 15, and 22 of a 28-day cycle [cycles 1–3], then days 1 and 15 [cycles 4–12]) plus LEN (20 mg PO QD, days 1–21/cycle for 12 cycles) and rituximab (375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1, then day 1 of cycles 2–5), or placebo (0.9% saline solution IV) plus LEN and rituximab. Primary endpoint is PFS (investigator assessed [INV] by Lugano 2014 criteria) for patients with FL. Secondary endpoints include PFS (INV) in the overall population, PET-CR rate (INV) at 90 days after last treatment, and OS in patients with FL.